ClinConnect ClinConnect Logo
Search / Trial NCT06584929

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial, called Rural Smoking Cessation, aims to find better ways to help people living in rural areas quit smoking. Smoking is a serious health issue in these communities, with higher rates of smoking-related illnesses and deaths compared to those in cities. The trial will look at different methods to see which ones work best for helping rural smokers successfully quit.

To participate, you need to be at least 21 years old, smoke at least 5 cigarettes a day, and have access to a smartphone or tablet. Unfortunately, if you have used nicotine replacement therapy (like patches or gum) in the past month, or if you are currently pregnant or breastfeeding, you won’t be able to join. Once the trial begins, participants can expect to try out various quitting methods and share their experiences, which will help researchers understand how to better support people in rural areas who want to stop smoking.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • ≥ 21 years
  • smoke ≥ 5 cigarettes per day
  • daily access to their own iPhone/Android smartphone or tablet
  • Exclusion Criteria:
  • past 30-day NRT use or contraindications listed on the NRT labels
  • currently pregnant/breastfeeding

About Masonic Cancer Center, University Of Minnesota

The Masonic Cancer Center at the University of Minnesota is a leading institution dedicated to cancer research, treatment, and prevention. As a National Cancer Institute-designated Comprehensive Cancer Center, it integrates innovative research with clinical practice to enhance patient care and advance medical knowledge. The center fosters collaboration among scientists, clinicians, and educators, focusing on multidisciplinary approaches to tackle the complexities of cancer. Through its commitment to cutting-edge clinical trials, the Masonic Cancer Center aims to translate scientific discoveries into effective therapies, ultimately improving outcomes for cancer patients locally and globally.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported